B cells linked to effective cancer immunotherapy

by Göran B Jönsson,Lund UniversityImmunofluorescence analysis of a melanoma tumor showing that B cells in B cell clusters express CXCR5, a marker for tertiary lymphoid structures. Credit: Göran

Updated on: December 20,2023

B cells linked to effective cancer immunotherapy

by Göran B Jönsson,Lund UniversityImmunofluorescence analysis of a melanoma tumor showing that B cells in B cell clusters express CXCR5, a marker for tertiary lymphoid structures. Credit: Göran

Updated on:December 20,2023

Engineering the immune system to tackle glioblastoma

by Sally Sapega,University of PennsylvaniaCredit: University of PennsylvaniaEach year, roughly 15,000 Americans are diagnosed with Glioblastoma Multiforme (GBM), the most common malignant primar

Updated on: December 22,2023

Engineering the immune system to tackle glioblastoma

by Sally Sapega,University of PennsylvaniaCredit: University of PennsylvaniaEach year, roughly 15,000 Americans are diagnosed with Glioblastoma Multiforme (GBM), the most common malignant primar

Updated on:December 22,2023

Multimodal sequencing achieves high-quality results from small volumes of frozen tumor specimens

byColumbia University School of Engineering and Applied ScienceA Circos plot representing the results of matched T-cell receptor sequencing collected on a patient undergoing anti-PD1 therapy. Co

Updated on: December 21,2023

Multimodal sequencing achieves high-quality results from small volumes of frozen tumor specimens

byColumbia University School of Engineering and Applied ScienceA Circos plot representing the results of matched T-cell receptor sequencing collected on a patient undergoing anti-PD1 therapy. Co

Updated on:December 21,2023

Targeted lung cancer drug shows promise in phase I/II clinical trial

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainEarly trials of the targeted drug repotrectinib suggest that it could help treat patients with a certain t

Updated on: December 19,2023

Targeted lung cancer drug shows promise in phase I/II clinical trial

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainEarly trials of the targeted drug repotrectinib suggest that it could help treat patients with a certain t

Updated on:December 19,2023

Pembrolizumab With COPDAC-28 Consolidation Increases PET Negativity in Classical Hodgkin Lymphoma

August 29, 2023Kyle DohertyThe addition of pembrolizumab to COPDAC-28 consolidation may augment responses to treatment in pediatric and young adult patients with high-risk classical Hodgkin lymphoma w

Updated on: October 12,2023

Pembrolizumab With COPDAC-28 Consolidation Increases PET Negativity in Classical Hodgkin Lymphoma

August 29, 2023Kyle DohertyThe addition of pembrolizumab to COPDAC-28 consolidation may augment responses to treatment in pediatric and young adult patients with high-risk classical Hodgkin lymphoma w

Updated on:October 12,2023

Are inflammatory bowel disease patients more at risk of colorectal cancer

In a recent study published in the journalFrontiers in Medicine, researchers analyzed data from a large cohort of inflammatory bowel disease (IBD) patients and compared the risk and frequency of

Updated on: October 30,2023

Are inflammatory bowel disease patients more at risk of colorectal cancer

In a recent study published in the journalFrontiers in Medicine, researchers analyzed data from a large cohort of inflammatory bowel disease (IBD) patients and compared the risk and frequency of

Updated on:October 30,2023

WHO moves step closer to cheaper breast cancer treatment

The World Health Organization has approved a biosimilar version of Trastuzumab—the drug used to treat breast cancer—that is generally 65 percent cheaper than the originalThe World Health Organization

Updated on: December 22,2023

WHO moves step closer to cheaper breast cancer treatment

The World Health Organization has approved a biosimilar version of Trastuzumab—the drug used to treat breast cancer—that is generally 65 percent cheaper than the originalThe World Health Organization

Updated on:December 22,2023

Racial disparity in pro-metastatic tumor microenvironment among women with residual breast cancer after NAC

byAmerican Association for Cancer ResearchCredit: Unsplash/CC0 Public DomainResidual tumors from Black patients with estrogen receptor (ER)-positive/HER2-negative primary breast cancer treated w

Updated on: December 17,2023

Racial disparity in pro-metastatic tumor microenvironment among women with residual breast cancer after NAC

byAmerican Association for Cancer ResearchCredit: Unsplash/CC0 Public DomainResidual tumors from Black patients with estrogen receptor (ER)-positive/HER2-negative primary breast cancer treated w

Updated on:December 17,2023

Three-country study provides insights into oral HPV incidence and risks in men

byH. Lee Moffitt Cancer Center & Research InstituteElectron micrograph of a negatively stained human papilloma virus (HPV) which occurs in human warts. Credit: public domainA new study has u

Updated on: November 15,2024

Three-country study provides insights into oral HPV incidence and risks in men

byH. Lee Moffitt Cancer Center & Research InstituteElectron micrograph of a negatively stained human papilloma virus (HPV) which occurs in human warts. Credit: public domainA new study has u

Updated on:November 15,2024

Talazoparib + enzalutamide beneficial in metastatic prostate cancer

by Elana GotkineFor patients with metastatic castration-resistant prostate cancer (mCRPC), treatment with talazoparib (TALA) plus enzalutamide (ENZA) is better than placebo (PBO) plus ENZA, according

Updated on: December 17,2023

Talazoparib + enzalutamide beneficial in metastatic prostate cancer

by Elana GotkineFor patients with metastatic castration-resistant prostate cancer (mCRPC), treatment with talazoparib (TALA) plus enzalutamide (ENZA) is better than placebo (PBO) plus ENZA, according

Updated on:December 17,2023

UGN-101 reviewed in real-world upper tract urothelial cancer setting

by Elana GotkineFor patients with upper tract urothelial cancers (UTUCs), the novel therapeutic UGN-101 seems to be effective, with an acceptable safety profile, according to research published online

Updated on: December 17,2023

UGN-101 reviewed in real-world upper tract urothelial cancer setting

by Elana GotkineFor patients with upper tract urothelial cancers (UTUCs), the novel therapeutic UGN-101 seems to be effective, with an acceptable safety profile, according to research published online

Updated on:December 17,2023

Researching a new treatment option for severe blood disorders of the bone marrow

by Anne Grimm,Leipzig UniversityCredit: CC0 Public DomainWhen people develop myelodysplastic neoplasms (MDS), the healthy maturation of blood cells is impaired. Severe forms, known as higher-ris

Updated on: March 21,2024

Researching a new treatment option for severe blood disorders of the bone marrow

by Anne Grimm,Leipzig UniversityCredit: CC0 Public DomainWhen people develop myelodysplastic neoplasms (MDS), the healthy maturation of blood cells is impaired. Severe forms, known as higher-ris

Updated on:March 21,2024